Mark S. Forman - 18 Apr 2022 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Reporting relationship: Chief Medical Officer
Issuer ticker: PASG
Reported as of: 18 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Apr 2022, 16:22:34 UTC
Prior SEC filing: 08 Apr 2022
Next SEC filing: 15 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Edgar Cale, Attorney-in-Fact

Key filing fact

Mark S. Forman filed Form 4 for Passage BIO, Inc. (PASG) on 20 Apr 2022.

Key facts

This page summarizes Mark S. Forman's Form 4 filing for Passage BIO, Inc. (PASG).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Apr 2022, 16:22.

Change

Previous filing in this sequence was filed on 08 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PASG transaction Derivative

Employee Stock Options (right to buy)

Award

Transaction value: $0
Shares: +136,000
Change %
Price: $0.000000
Shares after: 136,000
Date: 18 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 136,000
Exercise price: $2.61
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 25% of the total shares on April 18, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.